Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Permissive lung-protective ventilation in invasively ventilated adults

Official title: PERMISSive Lung-protective Ventilation in Critically Ill Invasively Ventilated Patients (PERMISS) - a Randomized Clinical Trial

Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT07837128 · Data updated 2026-11-12

This study tests whether lowering the breathing rate during mechanical ventilation is better than standard lung-protective ventilation for adults in the ICU who need invasive ventilation.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment926 (estimated)
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Academic / other
Locations2 sites (Amsterdam, NL and 1 other locations)
StatusRecruiting
StartedSeptember 2026
Main results expectedMarch 2029
Study endsSeptember 2029
Registry record updatedSeptember 23, 2026
Trial IDNCT07837128 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) in participating ICUs who are intubated and expected to require invasive ventilation for at least 24 hours.

Probably not a fit

Patients who have contraindications to permissive hypercapnia or who do not tolerate lower respiratory rates may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this international, multicenter trial, critically ill adults on invasive ventilation are randomized to either a permissive lung-protective strategy with a lower respiratory rate or to conventional lung-protective ventilation. The goal is to see if reducing ventilatory intensity can increase days alive and free from ventilation by day 28. The trial follows 28-day outcomes, with predefined safety limits for the lowest allowable respiratory rate. Participants are adults in ICUs expected to require ventilation for at least 24 hours; several common contraindications to permissive hypercapnia are excluded. The study uses a superiority framework to determine whether the lower RR approach improves patient-centered outcomes compared with standard care.

Why it matters

Potential benefit: If successful, the approach could reduce ventilation-related harm and improve chances of coming off the ventilator sooner.

How similar studies have gone: Previous work suggests that reducing ventilatory intensity may impact outcomes, but this trial tests a specific permissive strategy in a broad critically ill population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* admission to one of the participating intensive care units (ICUs);
* intubated and receiving invasive ventilation; and
* expected duration of ventilation of at least 24 hours (based on ICU admission diagnosis and clinical judgment).

Exclusion Criteria:

* age below 18 years;
* invasive ventilation before randomization \> 2 hours in the ICU or invasive ventilation \> 6 hours in the operating room or emergency department directly preceding the current ICU admission;
* receiving or planned to receive veno-venous, veno-arterial or arterio-venous extracorporeal membrane oxygenation (ECMO);
* contraindications for hypercapnia, such as ongoing cardiac ischemia (as defined in the guideline of the European Society of Cardiology), or having suspected or confirmed increased intracranial pressure due to (traumatic) brain injury, judged by the attending physician;
* having severe Chronic Obstructive Pulmonary Disease (COPD); GOLD classification III or IV or classified in group B or E of the GOLD ABE assessment tool);
* after cardiac arrest;
* suspected or confirmed pregnancy;
* having any neurologic diagnosis that can prolong duration of mechanical ventilation, e.g., Guillain-Barré syndrome, high spinal cord lesion or amyotrophic lateral sclerosis, multiple sclerosis, or myasthenia gravis;
* participation in another interventional trial using similar endpoints;
* previous randomization in this study;
* no informed consent or;
* admitted for palliative and terminal care.

Where it's running

  • Reinier De Graaf
    Delft, Nl, Netherlands
    Recruiting
  • Amsterdam UMC, locatie AMC
    Amsterdam, Nl, Netherlands
    Not yet recruiting

Study contacts

  • Principal investigator: Frederique Paulus, Full Professor — Amsterdam AMC, Amsterdam, the Netherlands
  • Study coordinator: Laura A. Buiteman-Kruizinga, PhD
  • Email: l.a.kruizinga@amsterdamumc.nl
  • Phone: +31627153843

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.